#NASDAQ #WallachBeth Capital #bioAffinity Technologies

WallachBeth Capital Closes $4 Million Financing for bioAffinity Technologies

On October 9, 2026, WallachBeth Capital LLC announced the closing of its previously planned registered direct offering for bioAffinity Technologies, Inc. This biotechnology company is known for its innovative, non-invasive healthcare solutions targeting early detection and monitoring of lung disease, an area of critical importance given the rising incidences of respiratory issues worldwide.

The financing consists of common stock shares sold at $6.122 each and includes pre-funded warrants. This direct offering was priced in compliance with Nasdaq rules, ensuring a seamless transaction process for all parties involved. Alongside this, bioAffinity also completed a concurrent private placement arrangement involving warrants that permit purchasing up to 980,072 shares of common stock at the same price, which will be accessible upon stockholder approval.

The total gross proceeds from this offering amounted to approximately $4 million before accounting for any placement fees or additional expenses. These funds are strategically earmarked for working capital and are expected to fuel sales growth for CyPath® Lung, the company's flagship non-invasive test for lung cancer. This innovative test aims to alleviate the burden of more invasive diagnostics, providing patients with early detection options that could potentially save lives.

WallachBeth Capital served as the sole placement agent throughout this process, underscoring its pivotal role in facilitating such transactions. Their expertise not only connects corporate clients with financing sources but also promotes collaborative growth within the healthcare sector.

The company utilized a